Who
Regina E. Groves
Director
Company insider
Files Form 4 as: Director, AtriCure; Director, Fulgent Genetics; Chief Executive Officer, REVA Medical.
In numbers
- Trades disclosed
- 44
- Buys
- 10
- Sells
- 5
- Bought
- $85K
- Sold
- $1.5M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 24 Sep 2015
- Last trade
- 11 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 14 Sep 2026 | ATRC AtriCureMedical Devices | SEC FORM 4 Sold | $288K5,313 at $54.22 | filing |
| 11 Sep 2026filed 14 Sep 2026 | ATRC AtriCureMedical Devices | SEC FORM 4 Sold | $288K5,313 at $54.22 | filing |
| 18 May 2026filed 20 May 2026 | ATRC AtriCureMedical Devices | SEC FORM 4 Code A | —6,144 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ATRC AtriCureMedical Devices | SEC FORM 4 Code A | —6,144 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | FLGT Fulgent GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —11,117 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | FLGT Fulgent GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —11,117 at $0.00 | filing |
| 6 Aug 2025filed 8 Aug 2025 | ATRC AtriCureMedical Devices | SEC FORM 4 Sold | $90K2,452 at $36.82 | filing |
| 19 May 2025filed 21 May 2025 | ATRC AtriCureMedical Devices | SEC FORM 4 Code A | —5,401 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | FLGT Fulgent GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —8,982 at $0.00 | filing |
| 16 May 2024filed 20 May 2024 | FLGT Fulgent Geneticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —5,481 at $0.00 | filing |
| 16 May 2024filed 20 May 2024 | FLGT Fulgent GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 13 May 2024filed 14 May 2024 | ATRC AtriCureMedical Devices | SEC FORM 4 Code A | —7,788 at $0.00 | filing |
| 25 May 2023filed 26 May 2023 | ATRC AtriCureMedical Devices | SEC FORM 4 Code A | —3,186 at $0.00 | filing |
| 18 May 2023filed 22 May 2023 | FLGT Fulgent Geneticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,759 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | FLGT Fulgent Geneticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | FLGT Fulgent GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 25 May 2022filed 27 May 2022 | ATRC AtriCureMedical Devices | SEC FORM 4 Code A | —3,564 at $0.00 | filing |
| 15 Sep 2021filed 17 Sep 2021 | ATRC AtriCureMedical Devices | SEC FORM 4 Sold | $236K3,156 at $74.73 | filing |
| 26 May 2021filed 28 May 2021 | ATRC AtriCureMedical Devices | SEC FORM 4 Sold | $303K4,208 at $71.95 | filing |
| 20 May 2021filed 24 May 2021 | ATRC AtriCureMedical Devices | SEC FORM 4 Code A | —1,749 at $0.00 | filing |
News
Analyzing AxoGen (NASDAQ:AXGN) & AtriCure (NASDAQ:ATRC)ATRC · tickerreport.com · 18 Oct 2026
0 headlines in the last 90 days name Regina E. Groves; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.